| The latest in antiretroviral therapy. | |
| | |
MedLine Citation:
|
PMID: 17160151 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The XVI International AIDS Conference (AIDS 2006), organized by the International AIDS Society (IAS), took place August 12-18 in Toronto, Canada. It was attended by over 26,000 participants from more than 170 countries and featured more than 4,500 abstracts as well as an array of community and cultural activities. The theme of the meeting was "Time to deliver", emphasizing the continued need and urgency in bringing effective HIV prevention and treatment strategies to those living with and affected by HIV/AIDS. The meeting's agenda was broad and included policy and programmatic topics as well as scientific research. This report focuses on reports presented at the conference that directly deal with antiretroviral therapy. This is primarily because of the nature of the venue where it is intended to be published (Drug News & Perspectives) as well as the expertise of the author. It is not a lack of recognition of the other equally important topics and discussions that took place at AIDS 2006. The author is solely responsible for the selection of topics and presentations to be included in this report. |
| | |
Authors:
|
Zelalem Temesgen |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: Drug news & perspectives Volume: 19 ISSN: 0214-0934 ISO Abbreviation: Drug News Perspect. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-12-12 Completed Date: 2007-02-15 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8809164 Medline TA: Drug News Perspect Country: Spain |
Other Details:
|
Languages: eng Pagination: 491-8 Citation Subset: IM |
Copyright Information:
|
(c) 2006 Prous Science. All rights reserved. |
Affiliation:
|
Mayo Clinic, Division of Infectious Diseases, 200 First Street SW, Rochester, MN 55905, USA. temesgen.zelalem@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-HIV Agents
/
pharmacology,
therapeutic use* Anti-Retroviral Agents / pharmacology, therapeutic use* Antibodies, Monoclonal / therapeutic use Antiretroviral Therapy, Highly Active Clinical Trials as Topic Cyclohexanes / therapeutic use Drugs, Investigational / pharmacology, therapeutic use* HIV Infections / drug therapy*, metabolism HIV-1 / drug effects* Humans Organic Chemicals / therapeutic use Piperazines / therapeutic use Pyridazines / therapeutic use Pyrimidines / therapeutic use Pyrrolidinones Receptors, Chemokine / antagonists & inhibitors Sulfonamides / therapeutic use Treatment Outcome Triazoles / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/1-((4,6-dimethyl-5-pyrimidinyl)carbonyl)-4-(4-(2-methoxy-4-(trifluoromethyl)phenyl)ethyl-3-methyl-1-piperazinyl)-4-methylpiperidine; 0/Anti-HIV Agents; 0/Anti-Retroviral Agents; 0/Antibodies, Monoclonal; 0/Cyclohexanes; 0/Drugs, Investigational; 0/MK 0518; 0/Organic Chemicals; 0/Piperazines; 0/Pyridazines; 0/Pyrimidines; 0/Pyrrolidinones; 0/Receptors, Chemokine; 0/Sulfonamides; 0/TNX-355; 0/Triazoles; 0/darunavir; 0/etravirine; 0/maraviroc |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronicles in drug discovery.
Next Document: Novel therapies in diabetes mellitus.